Clinical Trials Browser

Phase 3 × Stomach Neoplasms × 90 days × Clear all

NCT06346197 2026-04-21

CIME

Phase 3 Recruiting

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT07217704 2026-04-20

FAPI-GO

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03653507 2026-04-17

GLOW

Phase 3 Active not recruiting

507 enrolled 65 charts 2 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05152147 2026-04-17

HERIZON-GEA-01

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07518147 2026-04-08

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Phase 3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05568095 2026-04-02

STAR-221

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07488611 2026-03-25

PROGAIN

Phase 3 Recruiting

Gastrointestinal

Hyperphagia, Stomach Neoplasms

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03221426 2026-03-09

KEYNOTE-585

Phase 3 Completed

1,007 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06346392 2026-03-09

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04882241 2026-03-06

KEYNOTE-585

Phase 3 Completed

120 enrolled 17 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT05871099 2026-03-06

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT03675737 2026-02-27

KEYNOTE-859

Phase 3 Completed

1,579 enrolled 31 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07437573 2026-02-27

KLASS-09

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT05052801 2026-02-19

FORTITUDE-101

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03504397 2026-02-13

Spotlight

Phase 3 Active not recruiting

565 enrolled 63 charts 2 FDA

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT04871412 2026-01-30

POISE

Phase 3 Recruiting

GastrointestinalThoracic

Psychological Well-Being, Esophageal Neoplasms, Lung Neoplasms, Motor Activity, Stomach Neoplasms

NCT03399110 2026-01-27

XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Stomach Neoplasms